Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance

Reuters06-23

Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance

NEW YORK, June 23, 2025 -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 (Ac-225), demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi® (enzalutamide) and is effective in Xtandi® resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto® therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15672) on June 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2545445346?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-23 23:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2545445346","market":"fut","top_or_hot":-1,"title":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW YORK, June 23, 2025 -- <a href=\"https://laohu8.com/S/ATNM\">Actinium Pharmaceuticals, Inc.</a> (NYSE AMERICAN: ATNM) has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine &amp; Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 (Ac-225), demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi® (enzalutamide) and is effective in Xtandi® resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto® therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15672) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nActinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-23 23:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        NEW YORK, June 23, 2025 -- <a href=\"https://laohu8.com/S/ATNM\">Actinium Pharmaceuticals, Inc.</a> (NYSE AMERICAN: ATNM) has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine &amp; Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 (Ac-225), demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi® (enzalutamide) and is effective in Xtandi® resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto® therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15672) on June 23, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ATNM","symbol_name":"Actinium Pharmaceuticals, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nNDL2JX8J1:1","article_id":"2545445346","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2545445346","pubTimestamp":1750692620,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance. NEW YORK, June 23, 2025 -- Actinium Pharmaceuticals, Inc.  has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine & Molecular Imaging  annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 , demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi  and is effective in Xtandi resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.Dis","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ATNM":"Actinium Pharmaceuticals, Inc.","BK4139":"生物科技"},"translate_title":"Actinium Pharmaceuticals公布ATNM-400有希望的临床前数据，展示了在克服前列腺癌治疗耐药性方面的卓越疗效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ATNM":0.9},"content_text":"Actinium Pharmaceuticals Unveils Promising Preclinical Data for ATNM-400, Showcasing Superior Efficacy in Overcoming Prostate Cancer Treatment Resistance\n    \n\n        NEW YORK, June 23, 2025 -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) has announced new preclinical data for its prostate cancer candidate, ATNM-400, at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) annual meeting in New Orleans, Louisiana. The data indicate that ATNM-400, which utilizes the alpha-particle emitter Actinium-225 (Ac-225), demonstrates superior efficacy compared to the androgen receptor inhibitor Xtandi® (enzalutamide) and is effective in Xtandi® resistant prostate models. Additionally, ATNM-400 outperformed the PSMA-617 radiotherapies labeled with Lutetium-177 and Ac-225, showing potential to overcome resistance to Pluvicto® therapy. The presentation of these findings highlights ATNM-400's potential as a transformative therapy in prostate cancer treatment. Further details are available in the SNMMI presentation accessible on Actinium's website.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actinium Pharmaceuticals Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NY15672) on June 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2545445346","isCrawlerRequest":true}